UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_____________

FORM 8-K
_____________

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934


Date of report (Date of earliest event reported): September 29, 2006


Keryx Biopharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)
000-30929
(Commission File Number)
13-4087132
(IRS Employer Identification No.)


750 Lexington Avenue
New York, New York 10022
(Address of Principal Executive Offices)

(212) 531-5965
(Registrant's telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

£  
Written communications pursuant to Rule 425 under the Securities Act.
£  
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
£  
Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
£  
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

 
 
Item 8.01.  Other Events.

On October 4, 2006, Keryx Biopharmaceuticals, Inc. (“Keryx”) issued a press release announcing that Keryx entered into an exclusive licensing agreement (the "Agreement") with Kyowa Hakko Kogyo Co., Ltd. (“Kyowa”), a Tokyo-based company, for the worldwide development and commercialization rights (excluding Japan) to UCN-01, a novel multi-kinase inhibitor for the treatment of cancer that has demonstrated a synergistic effect with agents inhibiting the PI3K pathway, including perifosine. In accordance with the Agreement, Keryx has the right to make, use, sell, distribute, and sublicense UCN-01. In exchange for this license, Keryx will make upfront payments to Kyowa, as well as make payments upon the achievement of certain milestones. Keryx will also pay Kyowa a royalty based on product sales, if any. A copy of such press release is being filed as Exhibit 99.1 to this report and is incorporated herein by reference.
 
 
Item 9.01.    Financial Statements and Exhibits.
 
(d) 
 Exhibits  
     
The following exhibit is filed as a part of this report:
 
Exhibit
 
Number
 Description
     
99.1
   Press Release dated October 4, 2006.
 


SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
  Keryx Biopharmaceuticals, Inc.
  (Registrant)
 
 		  
 		  
 
Date: October 4, 2006   By:   /s/ Ronald C. Renaud, Jr. 
 
Ronald C. Renaud, Jr.
  Senior Vice President, Chief Financial Officer, Secretary and Treasurer
 



INDEX TO EXHIBITS
 
 
Exhibit
 
Number
 Description
     
99.1
   Press Release dated October 4, 2006.